---
title: "Zentalis doses first patient in Phase 3 ASPENOVA trial for Cyclin E1-positive PROC"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/285202157.md"
description: "Zentalis Pharmaceuticals has initiated the Phase 3 ASPENOVA trial by dosing the first patient. This trial will evaluate azenosertib in patients with Cyclin E1-positive platinum-resistant ovarian cancer, comparing it to standard chemotherapy. Approximately 420 patients will be enrolled, with the primary endpoint being progression-free survival (PFS). The trial is designed to support full approval in line with FDA requirements, following positive interim results from the DENALI Part 2a analysis."
datetime: "2026-05-05T12:03:00.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/285202157.md)
  - [en](https://longbridge.com/en/news/285202157.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/285202157.md)
---

# Zentalis doses first patient in Phase 3 ASPENOVA trial for Cyclin E1-positive PROC

**Zentalis dosed the first patient in the Phase 3 ASPENOVA trial evaluating azenosertib in Cyclin E1-positive platinum-resistant ovarian cancer.**

**Key Highlights:**

-   First patient dosed in ASPENOVA, a global Phase 3 randomized trial comparing azenosertib to standard single-agent chemotherapy.
-   ASPENOVA will enroll ~420 patients to compare azenosertib 400mg QD 5:2 vs investigator’s choice chemo; primary endpoint is PFS.
-   Trial designed as confirmatory study to support full approval, aligned with FDA requirements and DENALI Phase 2 accelerated pathway.
-   Azenosertib dose (400mg QD 5:2) selected based on DENALI Part 2a interim analysis showing differentiated response and comparable safety.

Original SEC Filing: Zentalis Pharmaceuticals, Inc. \[ ZNTL \] - 8-K - May. 05, 2026

**Disclaimer**

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.

### Related Stocks

- [ZNTL.US](https://longbridge.com/en/quote/ZNTL.US.md)
- [IHE.US](https://longbridge.com/en/quote/IHE.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [VHT.US](https://longbridge.com/en/quote/VHT.US.md)
- [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md)
- [IXJ.US](https://longbridge.com/en/quote/IXJ.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [XLV.US](https://longbridge.com/en/quote/XLV.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)

## Related News & Research

- [Bayer Granted Priority Review For Asundexian In Secondary Stroke Prevention](https://longbridge.com/en/news/286884841.md)
- [NeOnc Advances Glioma Programs and Strengthens Financial Position](https://longbridge.com/en/news/286826865.md)
- [Relay drug shows early promise against rare blood vessel diseases](https://longbridge.com/en/news/287094432.md)
- [Shah Capital Management Will Vote ‘No' Across Five Proposals On Novavax's June 18 Ballot - SEC Filing](https://longbridge.com/en/news/286565204.md)
- [UCB reports positive outcomes for bimekizumab in psoriatic arthritis](https://longbridge.com/en/news/286906544.md)